 JERSEY CITY, N.J., Oct. 11, 2022 GLOBE NEWSWIRE -- SCYNEXIS, Inc. NASDAQ: SCYX, a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced that interim data from the Phase 3 FURI study of oral ibrexafungerp for the treatment of patients intolerant of, or with fungal disease refractory to, standard antifungal therapy will be presented during IDWeek 2022 being held in Washington, D.C October 19-23, 2022. 